---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000039"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-06-17T23:59:59+00:00"
generated_at: "2026-06-25T00:56:09.295294+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Allogene shareholders elect directors, approve authorized share increase to 400M

## Summary
- Four Class I directors elected: Elizabeth Barrett, Arie Belldegrun, David Bonderman, David Chang.
- Advisory vote on executive compensation passed: 103,325,400 for, 7,596,094 against.
- Authorized common shares increased from 200M to 400M; amendment filed June 16, 2022.
- Stock option exchange program approved: 77,394,629 for, 33,536,201 against.
- Ernst & Young ratified as auditor for FY2022: 125,514,754 for, 49,928 against.

## SEC filing metadata
- accession: 0001737287-22-000039
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-06-17T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/0001737287-22-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000039/allo-20220615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000039
- JSON: https://secwatch.observer/filing/0001737287-22-000039.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.